I pædiatriske kliniske forsøg af op til 12 ugers varighed var forekomsten af epistaxis den samme hos patienter, der fik fluticasonfuroat, og hos patienter, der fik placebo.
In paediatric clinical studies of up to 12 weeks duration the incidence of epistaxis was similar between patients receiving fluticasone furoate and patients receiving placebo.